Table 1. Recent randomized trials of... | American Society of Hematology

Table 1.

Recent randomized trials of chemotherapy in the treatment of advanced Hodgkin lymphoma.

Regimen	No. of patients	CR, %	FFS, %	OS, %	Heme toxicity grade 3–4, %	*RAD, %**
*Patients receiving radiotherapy on protocol
**Statistically significant
Chemotherapy regimens: As referenced in article, escBEACOPP, escalated BEACOPP⁴; Modified Stanford V as by Gobbi et al; MDR, either ChlVPP/PABIOE (alternating) of CHlVPP/ EVA (hybrid)⁹; CEC, COPPEBVCAD.⁸
NS indicates not stated
MOPP/ABV	419	80	66 (5 y)	82	74.6	0
ABVD⁶⁶	433	76	63	81	63.6**	0
COPP/ABVD	260	85	69 (5 y)	83	71	64
BEACOPP	469	88	76	88	73	71
EscBEACOPP⁴	466	96	87	91**	98**	71
Mod Stanford V	107	76	54 (5 y)	82	29	66
MOPPEBVCAD	106	94	81	89	51**	47
ABVD¹⁰	122	89	78	90	21	62
Stanford V	259	ns	76 (5 y)	92	NS	53
ABVD¹²	261	NS	74	90	56	38
MDR	394	67	75 (3 y)	88 (3 y)	65**	40
ABVD⁹	394	68	75	90	56	38
BEACOPP	102	91	81 (5 y)**	92 (5 y)	54	44
CEC	102	83	78	91	48	43
ABVD⁸	103	84	68	84	34**	46

Regimen	No. of patients	CR, %	FFS, %	OS, %	Heme toxicity grade 3–4, %	*RAD, %**
*Patients receiving radiotherapy on protocol
**Statistically significant
Chemotherapy regimens: As referenced in article, escBEACOPP, escalated BEACOPP⁴; Modified Stanford V as by Gobbi et al; MDR, either ChlVPP/PABIOE (alternating) of CHlVPP/ EVA (hybrid)⁹; CEC, COPPEBVCAD.⁸
NS indicates not stated
MOPP/ABV	419	80	66 (5 y)	82	74.6	0
ABVD⁶⁶	433	76	63	81	63.6**	0
COPP/ABVD	260	85	69 (5 y)	83	71	64
BEACOPP	469	88	76	88	73	71
EscBEACOPP⁴	466	96	87	91**	98**	71
Mod Stanford V	107	76	54 (5 y)	82	29	66
MOPPEBVCAD	106	94	81	89	51**	47
ABVD¹⁰	122	89	78	90	21	62
Stanford V	259	ns	76 (5 y)	92	NS	53
ABVD¹²	261	NS	74	90	56	38
MDR	394	67	75 (3 y)	88 (3 y)	65**	40
ABVD⁹	394	68	75	90	56	38
BEACOPP	102	91	81 (5 y)**	92 (5 y)	54	44
CEC	102	83	78	91	48	43
ABVD⁸	103	84	68	84	34**	46